EndoRotor DEN (Direct Endoscopic Necrosectomy)Trial



Status:Recruiting
Conditions:Gastrointestinal
Therapuetic Areas:Gastroenterology
Healthy:No
Age Range:22 - Any
Updated:2/8/2019
Start Date:November 15, 2018
End Date:March 15, 2019
Contact:Eric Bannon
Email:ebannon@alvamed.com
Phone:781-710-8243

Use our guide to learn which trials are right for you!

Prospective, Trial Evaluating the Safety and Effectiveness of the Interscope Endorotor® System for Direct Endoscopic Necrosectomy of Walled Off Pancreatic Necrosis

A prospective, single arm, open label, multi-center, trial to evaluate the safety and
effectiveness of the Interscope EndoRotor® Resection System in subjects requiring direct
endoscopic necrosectomy (DEN) with walled off pancreatic necrosis (WOPN).

A prospective, single arm, open label, multi-center, trial to evaluate the safety and
effectiveness of the Interscope EndoRotor® Resection System in subjects requiring direct
endoscopic necrosectomy with walled off pancreatic necrosis (WOPN). Total enrollment 30
subjects with at least 15 enrolled in the US.

Subjects will be debrided with the EndoRotor either at the time of stent placement or post
placement at Investigator's discretion with a maximum of 4 EndoRotor procedures. A minimum of
2 days is required between each EndoRotor procedure and all procedures need to be completed
within a 14 (+7/-0) day period. Follow up is completed 21 (+/- 7) days after last EndoRotor
debridement procedure.

Inclusion Criteria:

1. Subjects who are >22; inclusive of males and females.

2. Patients with symptomatic pancreatic necrosis due to acute pancreatitis that have an
indication to undergo endoscopic necrosectomy after having undergone EUS-guided
drainage

3. Imaging suggestive of greater than or equal to 30% necrotic material

4. Walled off pancreatic necrosis size ≥6 cm and ≤22cm

5. Subject can tolerate repeated endoscopic procedures

6. Subject capable of giving informed consent.

7. Subjects with the ability to understand the requirements of the study, who have
provided written informed consent, and who are willing and able to return for the
required follow-up assessments through 21 (+/- 7) days, as indicated.

Exclusion Criteria:

1. Subject unable to give informed consent.

2. Subject is unwilling to return for repeated endoscopies.

3. Documented Pseudoaneurysm > 1cm within the WOPN

4. Intervening gastric varices or unavoidable blood vessels within the access tract
(visible using endoscopy or endoscopic ultrasound).

5. Dual antiplatelet therapy or therapeutic anticoagulation that cannot be withheld for
the procedure

6. Any condition that in the opinion of the investigator would create an unsafe clinical
situation that would not allow the patient to safely undergo an endoscopic procedure
(lack of medical clearance).

7. Pregnant or lactating women or women of childbearing potential who do not employ a
reliable method of contraception as judged by the Investigator, and/or are not willing
to use reliable contraception for the duration of study participation.

8. Patient is known to be currently enrolled in another investigational trial that could
interfere with the endpoint analyses of this trial.
We found this trial at
8
sites
1020 Walnut St
Philadelphia, Pennsylvania 19107
(215) 955-6000
Principal Investigator: Thomas Kowalski, MD
Phone: 215-955-8108
Thomas Jefferson University We are dedicated to the health sciences and committed to educating professionals,...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Chicago, Illinois 60637
Principal Investigator: Uzma Siddiqui, MD
Phone: 412-518-0149
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Frankfurt, 60590
Principal Investigator: Mireen Friedrich, MD PhD
Phone: +4969630183735
?
mi
from
Frankfurt,
Click here to add this to my saved trials
New Brunswick, New Jersey 08903
Principal Investigator: Michel Kahaleh, MD
Phone: 732-235-3247
?
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Palo Alto, California 94304
Principal Investigator: Joo Ha Hwang, MD
Phone: 408-829-5095
?
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Queens, New York 11040
Principal Investigator: Arvin Trindade, MD
Phone: 732-261-3401
?
mi
from
Queens, NY
Click here to add this to my saved trials
475 Brannan Street
San Francisco, California 94107
Principal Investigator: Kenneth Binmoeller, MD
Phone: 415-600-3542
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
Worcester, Massachusetts 01655
Principal Investigator: Jaroslav Zivny, MD
?
mi
from
Worcester, MA
Click here to add this to my saved trials